BridgeBio Pharma to Present Additional Analyses from the Phase 3 ATTRibute-CM Study of Acoramidis in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at the 2024 ISA Meeting marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.
BridgeBio Pharma Presents Additional Data and Analyses from its Phase 3 ATTRibute-CM Study in Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at ESC-HF, Including That Acoramidis Treatment Significantly Reduced All-Cause Mortality in a Pre-specified Sensitivity Analysis of the Entire Study Population marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.
BridgeBio Pharma Presents Additional Data and Analyses from its Phase 3 ATTRibute-CM Study in ... eagletribune.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from eagletribune.com Daily Mail and Mail on Sunday newspapers.
- In this exploratory substudy, treatment with acoramidis was associated with possible cardiac structural and functional improvement compared with placebo, with potential cardiac amyloid regression -.
- In this exploratory substudy, treatment with acoramidis was associated with possible cardiac structural and functional improvement compared with placebo, with potential cardiac amyloid regression -.